OKYO Pharma Granted U.S. Patent Covering OK-101's Potential for Treating Symptoms of Dry Eye Disease London and New York, NY

Pharma Granted U.S. Patent Covering OK-101's Potential for Treating Symptoms of Dry Eye Disease

and New York, NY, August 27, 2024 - OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing

innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular

segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy,

announced today the grant of a key U.S. Patent No. 12,053,501

which issued on August 6th entitled: "Methods for Treating Symptoms of Dry Eye Disease". The present disclosure

covers issued claims on OK-101's use to treat irritated, burning eyes and blurred vision in patients suffering from DED, strengthening

the Company's intellectual property position in this field.

are delighted with the issuance of this U.S. patent, which underscores the innovative potential of OK-101 to treat DED. This milestone

strengthens our intellectual property portfolio and positions OKYO Pharma for continued advancement in addressing significant unmet medical

needs," commented Dr. Gary S. Jacob, Ph.D., CEO of OKYO. "The issuance of this patent further solidifies OKYO Pharma's

commitment to advancing novel therapies that aim to improve outcomes for patients suffering from ocular pain and inflammation. The company

continues to explore strategic partnerships and collaborations to accelerate the development and commercialization of its pipeline candidates."

is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of

the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel

long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing efficacy

signals in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through

the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment.

OK-101 recently showed statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-blind, placebo-controlled

trial of OK-101 to treat DED.

Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED

and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel

molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway

for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please

visit www.okyopharma.com.

statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather

are based on the Company's current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words

such as anticipates,' expects,' intends,' plans,' believes,' seeks,'

estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees

of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's

control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking

statements. These and additional risks and uncertainties are described more fully in the company's

filings with the SEC, including those factors identified as "Risk Factors" in our most recent Annual Report on Form 20-F,

for the fiscal year ended March 31, 2023. The Company cautions security holders and prospective security holders not to place

undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The

forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company

will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events,

circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate

regulatory authority.